Bill Ackman
Valeant and Pershing take $290m hit over insider trading
January 2, 2018Manufacturing and Production, Sales and Marketing Bill Ackman, Pershing Square, Valeant, biotech, drugs, pharma, pharmaceutical
Valeant Pharmaceuticals will be hoping it can begin 2018 as a fresh start, after a turbulent few years, to say …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
